2.57% -0.0265

Sunshine Biopharma Inc (SBFM)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Sunshine Biopharma Inc Stock (SBFM) Company Profile

Sunshine Biopharma Inc

Healthcare (1086)

954-330-0684

333 LAS OLAS WAY, FORT LAUDERDALE

Nächster Verdiensttermin

Neueste SEC-Einreichungen

SBFM's Discussions on Twitter

Compare SBFM vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SBFM Sunshine Biopharma Inc	1.1235	4.46M	35.49M	-6.04M	-6.42M	-13.02
TAK Takeda Pharmaceutical Co Adr	18.25	58.50B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.79	42.84B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.19	40.68B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.67	30.40B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	502.79	21.36B	3.17B	1.29B	1.01B	27.09

Sunshine Biopharma Inc Aktie (SBFM) Neueste Nachrichten

Finanzdaten der Sunshine Biopharma Inc-Aktie (SBFM)

Sunshine Biopharma Inc (SBFM)

Sunshine Biopharma Inc Stock (SBFM) Company Profile

Compare SBFM vs TAK, TEVA, HLN, ZTS, UTHR

Sunshine Biopharma Inc Aktie (SBFM) Neueste Nachrichten

Price to sales forward of Sunshine Biopharma Inc. – BOATS:SBFMW - TradingView

Sunshine Biopharma Inc. SEC Filing (Sep 9, 2026) - Stock Titan

Sunshine Biopharma receives Canadian approval for atenolol tablets By Investing.com - Investing.com Nigeria

Sunshine Biopharma Announces Board Vacancy as Dr. Andrew Keller Steps Down After Term Ends - Kalkine Media

SBFM Looks 52.9% Undervalued on GF Value™ Despite Weak Fundamentals - GuruFocus

Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions - Cadillac News

Health Canada approves Atenolol, a drug used for high blood pressure and chest pain - Stock Titan

Sunshine Biopharma (NASDAQ: SBFM) could raise $31M from warrants - Stock Titan

Dr. Andrew Keller to Leave Sunshine Biopharma Board at Term End - TradingView

Sunshine Biopharma Inc. Announces Term Completion of Dr. Andrew Keller as Director - marketscreener.com

Sunshine Biopharma Inc. (SBFM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Sunshine Biopharma Inc. (SBFM) Key Financial Ratios – Valuation, Profitability & More - Value Research

Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer - The Batesville Daily Guard

Sunshine Biopharma Inc. Warrant (SBFMW) Peer Comparison – Compare with Others - Value Research

Sunshine (SBFMW) Market: Closes Nearly Flat at $0.05 in the Available Record; Levels: the Current Price Sits Inside the Supplied Technical RangeExhaustion Gap - vinanet.vn

Sunshine Biopharma wins Canadian approval for generic Enalapril tablets - Bitget

SBFM Looks 55.2% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus

BRIEF-Sunshine Biopharma Receives Canadian Regulatory Approval For Enalapril - Bitget

Sunshine Biopharma receives Canadian approval for generic enalapril By Investing.com - Investing.com Canada

Sunshine Biopharma receives Canadian approval for generic enalapril - Investing.com

Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market - Eagle-Tribune

EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug - Yahoo Finance

Sunshine (SBFM) Quarterly Performance Check: The Company Lists Its Latest Available Figures in the Reported Period; Session Reaction: The Stock Ends Up 1.79% in the Latest ReadingEarnings Momentum Score - vinanet.vn

101,973 Common Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-AUG-2026. - marketscreener.com

Sunshine Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com

SBFM Q1 2026 Earnings: Clinical-Stage Biotech Posts $0.25 Per-Share Loss as Shares Slip 4.17%Revenue Warning Signal - vinanet.vn

SBFM Q1 2026 Earnings: Reported Loss of $0.25 Per Share as Stock Declines 4.17%Pre-Earnings Setup - Vinanet

Sunshine Biopharma Inc (NASDAQ: SBFM) Share Price, SBFM Stock News, SBFM Share Price & Updates - kalkine.ca

SBFM Q1 2026 Earnings: Net Loss of -$0.25 Per Share as Pre-Revenue Oncology Developer Presses OnForward Guidance Trends - vinanet.vn

L1 Capital (SBFM) discloses 4.99% Sunshine Biopharma stake plus large warrant position - Stock Titan

Sunshine Biopharma (SBFM) investors cap warrant-driven stake at 9.99% - Stock Titan

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market - The Lawton Constitution

Sunshine Biopharma (SBFM) Holds Gains at $1.23 as Stock Stays Rangebound Between Key LevelsActive ETF Flow - dars.gov.et

SBFM Q1 2026 Earnings: Net Loss of $0.25 Per Share Highlights Pre-Commercial Biotech StageGuidance Downgrade Alert - vinanet.vn

SBFM Stock Holds Support As Traders Eye Next Move - timothysykes.com

SBFM Stock Holds Support As Sunshine Biopharma Tightens Cash Control - StocksToTrade

SBFM Stock Holds Range As Traders Weigh Weak Margins - timothysykes.com

SBFM Stock Slides As Traders Focus On Cash Runway And Volatility - StocksToTrade

SBFM Stock Pops As Health Canada Greenlights New Generics - StocksToTrade

Amoxicillin Market Estimated at $4.9B as Canada Shipments Begin - Stock Titan

Sunshine Biopharma Inc. Revenue Breakdown – NASDAQ:SBFMW - TradingView

SBFM Looks 84.2% Undervalued on GF Value™ Despite Distressed Fun - GuruFocus

Sunshine Biopharma receives Canadian approval for generic dienogest By Investing.com - Investing.com Nigeria

Sunshine Biopharma receives Canadian approval for generic dienogest - Investing.com

Sunshine Biopharma's 2mg Tablet for Endometriosis Pain Wins Canadian Approval - Stock Titan

EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval - Benzinga

SBFM Q2'26 Earnings: EPS estimate is (1.20) USD - TradingView

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval - finance.yahoo.com

Sunshine Biopharma wins Canadian approval for generic Dienogest tablets - Bitget

Sunshine Biopharma cuts exercise price of outstanding Series B warrants to $1.22 - Bitget

Sunshine Biopharma Inc. (SBFM) Q1 2026 Earnings: Widening Losses as Pre‑Revenue Biotech Navigates Pipeline MilestonesNet Profit Margin - dars.gov.et

Finanzdaten der Sunshine Biopharma Inc-Aktie (SBFM)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie SBFM